CN101401830B - Preparation method for extracting flavone from purslane and uses thereof - Google Patents
Preparation method for extracting flavone from purslane and uses thereof Download PDFInfo
- Publication number
- CN101401830B CN101401830B CN2008101976472A CN200810197647A CN101401830B CN 101401830 B CN101401830 B CN 101401830B CN 2008101976472 A CN2008101976472 A CN 2008101976472A CN 200810197647 A CN200810197647 A CN 200810197647A CN 101401830 B CN101401830 B CN 101401830B
- Authority
- CN
- China
- Prior art keywords
- purslane
- extract
- flavonoids
- cisplatin
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 229930003944 flavone Natural products 0.000 title claims 3
- 235000011949 flavones Nutrition 0.000 title claims 3
- 235000001855 Portulaca oleracea Nutrition 0.000 title abstract description 46
- 241000219304 Portulacaceae Species 0.000 title abstract 7
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 title 1
- 150000002212 flavone derivatives Chemical class 0.000 title 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 title 1
- 229960004316 cisplatin Drugs 0.000 claims abstract description 25
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 24
- 230000006378 damage Effects 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 17
- 210000003734 kidney Anatomy 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000001914 filtration Methods 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 14
- 238000010992 reflux Methods 0.000 claims description 12
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 208000014674 injury Diseases 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 150000002213 flavones Chemical class 0.000 claims 2
- 241000186216 Corynebacterium Species 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 abstract description 36
- 150000002215 flavonoids Chemical class 0.000 abstract description 36
- 235000017173 flavonoids Nutrition 0.000 abstract description 36
- 210000004369 blood Anatomy 0.000 abstract description 22
- 239000008280 blood Substances 0.000 abstract description 22
- 239000002246 antineoplastic agent Substances 0.000 abstract description 14
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 14
- 241000699670 Mus sp. Species 0.000 abstract description 12
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 239000000469 ethanolic extract Substances 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract 1
- 244000234609 Portulaca oleracea Species 0.000 description 39
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 229940064064 purslane extract Drugs 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 206010061481 Renal injury Diseases 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 208000037806 kidney injury Diseases 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 102000017955 Regucalcin Human genes 0.000 description 2
- 108050007056 Regucalcin Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940068052 ginkgo biloba extract Drugs 0.000 description 2
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- -1 terpene lactones Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000219295 Portulaca Species 0.000 description 1
- 241000353135 Psenopsis anomala Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 206010062903 Urethritis noninfective Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- CMPGARWFYBADJI-UHFFFAOYSA-L tungstic acid Chemical compound O[W](O)(=O)=O CMPGARWFYBADJI-UHFFFAOYSA-L 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种从马齿苋中提取黄酮的制备方法和应用,药物特征是马齿苋乙醇提取物。其制备步骤为:①将马齿苋洗净、晾干;②将马齿苋剪成短棒;③用乙醇回流提取马齿苋中的黄酮;④抽滤提取液;⑤浓缩抽滤所得液体。该提取物的应用方法如下:①接种瘤细胞;②将小鼠随机分为四组;③分组处理;④取血、称瘤重;⑤获取血清;⑥血尿素氮含量测定;⑦血肌酐含量测定。经动物实验证实该提取物能有效抵抗抗癌药物顺铂所致的肾损伤。此外,该提取物给药方便,效果良好,无毒副作用。而马齿苋来源广泛,价格低廉,使得本提取物具有物美价廉的优点。The invention discloses a preparation method and application of extracting flavonoids from purslane. The medicinal feature is the ethanol extract of purslane. The preparation steps are as follows: ①washing and drying the purslane; ②cutting the purslane into short sticks; ③refluxing with ethanol to extract the flavonoids in the purslane; ④suction filtering the extract; . The application method of the extract is as follows: ① Inoculate tumor cells; ② Divide the mice into four groups at random; ③ Group treatment; ④ Take blood and weigh the tumor; ⑤ Obtain serum; Determination. Animal experiments have confirmed that the extract can effectively resist kidney damage caused by the anticancer drug cisplatin. In addition, the extract is convenient to administer, has good effect, and has no toxic and side effects. Purslane has a wide range of sources and low price, so that the extract has the advantages of high quality and low price.
Description
技术领域technical field
本发明涉及医药技术领域,更具体涉及一种从马齿苋中提取总黄酮的制备方法,同时还涉及马齿苋总黄酮的用途。The invention relates to the technical field of medicine, more specifically to a preparation method for extracting total flavonoids from purslane, and also relates to the application of total flavonoids from purslane.
背景技术Background technique
1.抗肿瘤药物易导致肾损害1. Antineoplastic drugs can easily cause kidney damage
抗肿瘤药物的应用虽然对肿瘤的控制有较大的帮助,但其对肾脏的损伤作用却是一个不容忽视的问题。抗肿瘤药物对肾脏损伤的机制如下:Although the application of antitumor drugs is of great help to the control of tumors, its damage to the kidneys is a problem that cannot be ignored. The mechanism of antineoplastic drugs on kidney damage is as follows:
首先,原尿的浓缩使尿中药物浓度远高于血药浓度,易产生结晶,阻塞肾小管。同时,肾脏重量仅占体重的0.4%,而血流量却约占心搏血量的25%。因此,当对肾脏有害的抗肿瘤药物及其代谢产物随血流到达肾脏时就更容易使之产生病变。First of all, the concentration of the original urine makes the drug concentration in the urine much higher than the blood drug concentration, which is easy to produce crystals and block the renal tubules. At the same time, the weight of the kidneys accounts for only 0.4% of the body weight, while the blood flow accounts for about 25% of the cardiac blood volume. Therefore, when antineoplastic drugs and their metabolites that are harmful to the kidneys reach the kidneys with the blood stream, they are more likely to cause pathological changes.
另一方面,肾脏代谢酶活性高。有些抗肿瘤药物在此转化时产生有毒物质。抗肿瘤药物引起的泌尿系统反应主要有尿道内刺激反应和肾实质的损害(韩涛.抗肿瘤药物的不良反应及其防治[J].首都医药,2008,(4):45-48)。On the other hand, kidney metabolic enzyme activity is high. Some antineoplastic drugs produce toxic substances during this transformation. Urinary system reactions caused by antineoplastic drugs mainly include urethral irritation and renal parenchyma damage (Han Tao. Adverse reactions of antineoplastic drugs and their prevention [J]. Capital Medicine, 2008, (4): 45-48).
更深入的实验表明,抗肿瘤药物引起肾脏损伤的主要成分是其水解代谢产物。抗肿瘤药物的亲核氨基可与水分子作用产生大量的自由基,造成细胞膜和线粒体的氧化损伤,功能丧失.。除引起氧化损伤外,抗肿瘤药物在肾脏代谢过程中可以抑制肾小管刷状缘和有机离子转运系统,特别是Na+—K+—ATP酶活性,减少了肾近曲小管对葡萄糖的重吸收,使上皮细胞水肿变性。有些学者认为,抗肿瘤药物还可以抑制肾皮质结合蛋白调节素(Ca+—binding protein regucalcin)mRNA表达,肾皮质钙含量增加,造成细胞内钙稳态失衡,造成细胞损伤(KinYK,Byun HS,Kim YH.Toxical Appl.Pharmacol.1995,130(1):19)。More in-depth experiments have shown that the main components of antineoplastic drugs causing kidney damage are their hydrolytic metabolites. The nucleophilic amino group of antineoplastic drugs can interact with water molecules to generate a large number of free radicals, causing oxidative damage to cell membranes and mitochondria, and loss of function. In addition to causing oxidative damage, antineoplastic drugs can inhibit the renal tubular brush border and organic ion transport system, especially the activity of Na + —K + —ATPase during renal metabolism, and reduce the reabsorption of glucose by renal proximal tubules , so that epithelial cell edema degeneration. Some scholars believe that antineoplastic drugs can also inhibit the expression of renal cortex-binding protein regucalcin (Ca + —binding protein regucalcin) mRNA, increase the calcium content of renal cortex, cause intracellular calcium homeostasis imbalance, and cause cell damage (KinYK, Byun HS, Kim YH. Toxical Appl. Pharmacol. 1995, 130(1): 19).
如今,抗肿瘤药物的使用越来越多,肾损伤成为大家日益关注的问题。因此,肾损伤保护药物的研究成为当今—大热门课题。Nowadays, with the increasing use of antineoplastic drugs, kidney injury has become a growing concern. Therefore, the study of renal damage protection drugs has become a hot topic today.
2.黄酮类化合物的特殊生物学活性2. Special biological activity of flavonoids
研究表明,广泛存在于自然界的植物性黄酮类化合物具有抗氧化作用,而且其抗氧化效果与其结构有关(王姝梅.天然黄酮类化合物的抗氧化作用及构效关系[J].Strait Pharmaceutical Journal,2004,16(3),10-13)。目前,有些研究探讨了一些植物中的黄酮对抗抗肿瘤药物所致肾损伤的效果及其作用机制。已有文献报道枸杞总黄酮具有一定的活血化瘀、降血脂、降血糖和提高免疫功能的作用;山楂叶总黄酮可有效防治心血管疾病、清除氧自由基、降脂、利尿和增强耐缺氧能力;大豆异黄酮对肾脏的保护作用也是比较热门的一个研究课题,大豆蛋白对动物和人类多囊肾,糖尿病性肾病,肾病综合症等多种肾脏疾病均有益(苏波,蔡东联.大豆异黄酮对肾脏疾病的保护作用[J].Medical Recapitulate,2003,9(10):611-612)。此外,熊小明等则证实了银杏叶提取物,一种含黄酮类及萜内酯类化合物具有抗顺铂肾毒性作用(熊小明等.银杏叶提取物治疗顺铂所致大鼠肾损伤[J].中国医院药学,2008,28(4):265-268)。Studies have shown that plant-based flavonoids widely present in nature have antioxidant effects, and their antioxidant effects are related to their structures (Wang Shumei. Antioxidant effects and structure-activity relationships of natural flavonoids [J]. Strait Pharmaceutical Journal, 2004 , 16(3), 10-13). At present, some studies have explored the effect and mechanism of flavonoids in some plants against kidney injury caused by antineoplastic drugs. It has been reported in the literature that the total flavonoids of Lycium barbarum can promote blood circulation and remove blood stasis, lower blood fat, lower blood sugar and improve immune function; the total flavonoids of hawthorn leaves can effectively prevent and treat cardiovascular diseases, scavenge oxygen free radicals, reduce lipids, diuresis and enhance deficiency tolerance Oxygen capacity; the protective effect of soybean isoflavones on the kidney is also a relatively popular research topic. Soy protein is beneficial to various kidney diseases such as animal and human polycystic kidney disease, diabetic nephropathy, and nephrotic syndrome (Su Bo, Cai Donglian. Soybean The protective effect of isoflavones on kidney disease [J]. Medical Recapitulate, 2003, 9(10): 611-612). In addition, Xiong Xiaoming et al. confirmed that Ginkgo biloba extract, a compound containing flavonoids and terpene lactones, has anti-cisplatin nephrotoxicity (Xiong Xiaoming et al. Ginkgo biloba extract treats cisplatin-induced renal injury in rats[ J]. Chinese Hospital Pharmacy, 2008, 28(4): 265-268).
3.马齿苋及其提取物的研究进展3. Research progress of purslane and its extract
马齿苋(PortulacaOleraceaL.)又名蚂蚁菜、长命菜、瓜子菜、五行草等,系马齿苋科一年生草本植物,在我国几乎各省均有分布,资源丰富,采集方便。它是我国的传统中药,在民间已有数千年的应用历史。马齿苋中的有效成分如生物碱、多糖、蒽醌等,可防治心血管疾病;马齿苋还有降血脂,抗衰老等作用,并能增强机体免疫功能;马齿苋还含有多种维生素、矿物质、蛋白质和氨基酸,具有抗动脉粥样硬化、抗菌、抗肿瘤和抗氧化等作用。Purslane (Portulaca Oleracea L.), also known as ant vegetable, long-lived vegetable, melon seed vegetable, five-element grass, etc., is an annual herbaceous plant of the family Portulaca. It is distributed in almost every province in my country. It is rich in resources and easy to collect. It is a traditional Chinese medicine in my country and has been used in the folk for thousands of years. The active ingredients in purslane, such as alkaloids, polysaccharides, anthraquinone, etc., can prevent and treat cardiovascular diseases; Vitamins, minerals, proteins and amino acids, have anti-atherosclerosis, anti-bacterial, anti-tumor and anti-oxidation effects.
马齿苋乙醇提取物主要成分为黄酮,且其中总黄酮含量高达6.37%(魏循,王仲英.马齿苋总黄酮含量的测定[J].Chinese Journal Of Spectroscopy Laboratory,2003(1),20(1):128-129)。但经检索,迄今为止,未见有马齿苋提取物抗顺铂所致肾损伤的报道。The main component of purslane ethanol extract is flavonoids, and the total flavonoids content is as high as 6.37% (Wei Xun, Wang Zhongying. Determination of total flavonoids content in purslane [J]. Chinese Journal Of Spectroscopy Laboratory, 2003 (1), 20 ( 1): 128-129). However, after retrieval, so far, there has been no report of purslane extract resisting cisplatin-induced kidney injury.
在此基础之上,我们对马齿苋提取物的肾保护作用进行研究,通过动物实验证实本发明对化疗药物所致的肾损伤确实有很好的保护作用。On this basis, we study the renal protective effect of purslane extract, and prove that the present invention has a good protective effect on renal injury caused by chemotherapy drugs through animal experiments.
发明内容Contents of the invention
本发明的目的是在于提供了一种从马齿苋中提取总黄酮的制备方法。该方法利用黄酮为脂溶性物质的特点,使用75%的乙醇回流提取,工艺简单易行;而提取液的回旋浓缩技术也已成熟。而且应用此法总黄酮的提取率较高,还能保持其生物活性,以保证之后实验的进行。此外,马齿苋来源广泛,价格低廉,因而使得提取物物美价廉。The purpose of the present invention is to provide a preparation method for extracting total flavonoids from purslane. The method utilizes the feature that flavonoids are fat-soluble substances, and uses 75% ethanol to reflux to extract, and the process is simple and easy; and the cyclone concentration technology of the extract is also mature. Moreover, the extraction rate of total flavonoids by this method is high, and its biological activity can be maintained to ensure the subsequent experiments. In addition, purslane is widely available and inexpensive, making the extract affordable.
本发明的另一个目的是在于提供了一种从马齿苋中提取的总黄酮在制备治疗或预防(抵抗)顺铂所致肾损伤的药物中的应用。经动物实验证明该提取物效果显著,给药组小鼠血尿素氮浓度明显低于未给药组,高剂量组小鼠血尿素氮浓度也明显低于低剂量组。该提取物采用常规口服剂型,给药方便,无痛苦,没有后遗症,且几乎无任何毒副作用。Another object of the present invention is to provide an application of total flavonoids extracted from purslane in the preparation of medicines for treating or preventing (resisting) kidney damage caused by cisplatin. Animal experiments have proved that the extract has a significant effect. The blood urea nitrogen concentration of the mice in the drug-administered group is significantly lower than that of the non-medicated group, and the blood urea nitrogen concentration of the mice in the high-dose group is also significantly lower than that in the low-dose group. The extract adopts a conventional oral dosage form, and the administration is convenient, painless, without sequelae, and almost without any toxic and side effects.
为了实现上述目的,本发明采用以下技术措施:In order to achieve the above object, the present invention adopts the following technical measures:
一种从马齿苋中提取总黄酮的制备步骤是:A preparation step for extracting total flavonoids from purslane is:
1.将新鲜马齿苋用清水洗净摘取并除去其叶子和根部,沥干水分并晾于避光通风处直至完全除去其表面水分,时间控制在20~24h。1. Wash the fresh purslane with clean water, remove its leaves and roots, drain the water and dry it in a dark and ventilated place until the surface moisture is completely removed. The time is controlled within 20-24 hours.
2.将晾干的马齿苋茎部剪成0.8-1.2cm左右的短棒状。2. Cut the stem of the dried purslane into a short stick shape of about 0.8-1.2cm.
3.在马齿苋中加入6倍体积的70%乙醇(质量比),78-82℃条件下水浴回流时间控制在1-3小时,回流2-4次。3. Add 6 times the volume of 70% ethanol (mass ratio) to the purslane, control the reflux time in the water bath at 78-82°C for 1-3 hours, and reflux for 2-4 times.
4.将回流后所得溶液抽滤,留下滤液,弃杂质,然后将2-4次回流并抽滤所得到的液体混匀。4. Suction filter the solution obtained after reflux, leave the filtrate, discard impurities, and then reflux and suction filter the obtained liquid for 2-4 times and mix well.
5.温度控制在60-65℃条件下在旋转蒸发仪中进行旋转蒸发上述步骤4所得液体,得到了一种总黄酮的浓缩液。5. Temperature control Rotary evaporation of the liquid obtained in the above step 4 was carried out in a rotary evaporator under the condition of 60-65° C. to obtain a concentrated solution of total flavonoids.
总黄酮作为在制备治疗或预防(抵抗)顺铂所致肾损伤的药物中的应用基本过程是:The basic process of the application of total flavonoids in the preparation of medicines for treating or preventing (resisting) cisplatin-induced kidney damage is:
1.接种瘤细胞1. Inoculation of tumor cells
雌性昆明小鼠40只,体重(25±2)g,实验第一天,每只小鼠均腋腔注射S180小鼠腹水(含瘤细胞株)0.2ml。40 female Kunming mice, weighing (25±2) g, were injected with 0.2 ml of S 180 mouse ascites (containing tumor cell line) in the axillary cavity on the first day of the experiment.
2.分组2. Grouping
将接种后的小鼠随机分为4组(生理盐水对照组、顺铂损伤模型对照组、低剂量马齿苋药物治疗组、高剂量马齿苋药物治疗组),每组10只。The inoculated mice were randomly divided into 4 groups (normal saline control group, cisplatin injury model control group, low dose purslane drug treatment group, high dose purslane drug treatment group), 10 in each group.
3.分组处理3. Packet processing
小鼠分组处理情况如下:The mice were divided into groups as follows:
1)生理盐水对照组:接种24小时后,每天用生理盐水灌胃0.5ml,一共7天;1) Normal saline control group: 24 hours after inoculation, 0.5ml of normal saline was administered into the stomach every day for a total of 7 days;
2)顺铂损伤模型对照组:接种24小时后,每天用生理盐水灌胃0.5ml,连续7天,于第4天一次性腹腔注射顺铂(12.0mg/kg);2) Cisplatin injury model control group: 24 hours after inoculation, 0.5ml of normal saline was administered into the stomach every day for 7 consecutive days, and cisplatin (12.0mg/kg) was injected intraperitoneally once on the fourth day;
3)马齿苋总黄酮低剂量给药组:每天用马齿苋提取物按照小鼠体重5mg/kg的比例灌胃一次(0.5ml),连续7天,于第4天一次性腹腔注射顺铂(12.0mg/kg);3) Low-dose administration group of total flavonoids of purslane: the extract of purslane was administered once a day (0.5ml) according to the ratio of mouse body weight 5mg/kg, for 7 consecutive days, and on the 4th day, a one-time intraperitoneal injection was given. Platinum (12.0mg/kg);
4)高剂量马齿苋提取物治疗组:每天用马齿苋提取物按照小鼠体重20mg/kg比例灌胃一次(0.5ml),连续7天,于第4天一次性腹腔注射顺铂(12.0mg/kg)。4) High-dose purslane extract treatment group: use purslane extract once a day (0.5ml) according to the ratio of mouse body weight 20mg/kg, for 7 consecutive days, and inject cisplatin ( 12.0 mg/kg).
本发明具有以下优点:The present invention has the following advantages:
1.本发明涉及的马齿苋提取物是以马齿苋作为原料母体经乙醇提取和进步的浓缩得到。原料来源广泛,价格低廉;1. The purslane extract that the present invention relates to is obtained through ethanol extraction and progressive concentration with purslane as raw material matrix. Wide range of sources of raw materials and low prices;
2.马齿苋总黄酮的提取、浓缩工艺简单易行,技术成熟;2. The extraction and concentration process of total flavonoids of purslane is simple and easy, and the technology is mature;
3.马齿苋总黄酮作为保护化疗药物所致肾损伤的药物开发,这不仅是对祖国医学理论的丰富,而且也是对马齿苋有效部位的深入研究,因此,具有重要的社会和经济效益;3. The development of total flavonoids of purslane as a drug to protect kidney damage caused by chemotherapy drugs is not only an enrichment of the medical theory of the motherland, but also an in-depth study of the effective parts of purslane. Therefore, it has important social and economic benefits ;
4.马齿苋总黄酮不仅能有效治疗化疗药物引起的肾损伤,而且有降低血脂,抗衰老等作用,并能增强机体的免疫功能;4. The total flavonoids of purslane can not only effectively treat kidney damage caused by chemotherapy drugs, but also reduce blood fat, anti-aging and other effects, and can enhance the immune function of the body;
5.马齿苋总黄酮的高效抗肾损伤活性在于其具有清除自由基,提高抗氧化物酶活性,降低脂质过氧化物水平以及免疫调节等多方面功效;5. The high-efficiency anti-kidney damage activity of the total flavonoids of purslane lies in its multiple effects such as scavenging free radicals, increasing antioxidant enzyme activity, reducing lipid peroxide levels, and immune regulation;
6.经检索,马齿苋总黄酮的急性毒性试验表明其几乎无毒副作用;6. After searching, the acute toxicity test of the total flavonoids of purslane shows that it has almost no toxic side effects;
7.本发明采用口服给药方式,给药方便,无痛苦,没有后遗症。7. The present invention adopts an oral administration mode, which is convenient, painless, and without sequelae.
具体实施方式Detailed ways
一、一种从马齿苋中提取总黄酮的流程是:One, a kind of flow process that extracts total flavonoids from purslane is:
新鲜马齿苋加工→回流提取→抽滤→上清液→浓缩→纯化Fresh purslane processing → reflux extraction → suction filtration → supernatant → concentration → purification
具体步骤如下:Specific steps are as follows:
1.将新鲜马齿苋用清水洗净摘取并除去其叶子和根部,沥干水分并晾于避光通风处直至完全除去其表面水分。时间控制在20或21或22或23或24h。1. Wash the fresh purslane with clean water, remove its leaves and roots, drain the water and hang it in a dark and ventilated place until the surface moisture is completely removed. The time is controlled at 20 or 21 or 22 or 23 or 24 hours.
2.将晾干的马齿苋茎部剪成0.8或0.9或1或1.1或1.2cm的短棒状。2. Cut the dried purslane stems into 0.8 or 0.9 or 1 or 1.1 or 1.2 cm short sticks.
3.在马齿苋中加入6倍体积的70%乙醇(质量比),78或79或80或81或82℃条件下水浴回流1或2或3小时,回流4或3或2次。3. Add 6 times the volume of 70% ethanol (mass ratio) to the purslane, reflux in a water bath at 78 or 79 or 80 or 81 or 82°C for 1 or 2 or 3 hours, and reflux for 4 or 3 or 2 times.
4.将回流后所得溶液抽滤,留下滤液,弃杂质,然后将三次回流并抽滤所得到的液体混匀。4. Suction filter the solution obtained after reflux, leave the filtrate, discard impurities, and then mix the liquid obtained by reflux and suction filtration three times.
5.温度控制在60或61或62或63或64或65℃条件下旋转蒸发步骤4所得液体,得到浓缩液。5. Temperature control Rotary evaporation of the liquid obtained in step 4 at 60 or 61 or 62 or 63 or 64 or 65° C. to obtain a concentrated solution.
二、马齿苋总黄酮含量的测定2. Determination of total flavonoid content in purslane
1.马齿苋黄酮鉴定1. Identification of purslane flavonoids
加镁粉和盐酸显色反应:取样品少许,加95%乙醇1-3ml,置其磨口塞的试管中,室温(23℃~27℃)下振荡,加少许镁粉振摇,再滴加数滴浓盐酸,1~2min后呈红色,证明所提取物中含有黄酮类化合物。Add magnesium powder and hydrochloric acid color reaction: take a little sample, add 1-3ml of 95% ethanol, put it in a test tube with a ground plug, shake at room temperature (23°C-27°C), add a little magnesium powder to shake, then drop Add a few drops of concentrated hydrochloric acid, and it turns red after 1-2 minutes, which proves that the extract contains flavonoids.
2.马齿苋总黄酮的测定2. Determination of total flavonoids in purslane
①标准曲线的制备① Preparation of standard curve
准确称取芦丁对照品200mg,用70%乙醇(质量比)溶解,定容于100ml容量瓶中,摇匀。准确吸取10ml,置于100ml容量瓶中,用水定容,得到0.2mg/ml的标准溶液。准确吸取标准溶液0.4、0.8、1.2、1.6、2.0、2.4ml,分别置于10ml容量瓶中,加水至2.4ml,加入质量分数为5%的亚硝酸钠0.4ml,混匀,放置6min,加入质量分数为10%硝酸铝0.4ml,混匀,放置6min,加入质量分数为4.3%氢氧化钠4.0ml,用水稀释至刻度,摇匀,放置15min,以空白管为对照,用紫外分光光度计,在500nm波长处测定吸光度,得到浓度C与吸光度A的校准曲线:C=72.714A-0.5268,r=0.9991。Accurately weigh 200 mg of the rutin reference substance, dissolve it with 70% ethanol (mass ratio), set the volume in a 100 ml volumetric flask, and shake well. Accurately draw 10ml, place it in a 100ml volumetric flask, and dilute to volume with water to obtain a 0.2mg/ml standard solution. Accurately draw 0.4, 0.8, 1.2, 1.6, 2.0, 2.4ml of the standard solution, place them in a 10ml volumetric flask, add water to 2.4ml, add 0.4ml of sodium nitrite with a mass fraction of 5%, mix well, place for 6min, add The mass fraction is 0.4ml of 10% aluminum nitrate, mix well, stand for 6min, add 4.3% sodium hydroxide 4.0ml, dilute with water to the mark, shake well, stand for 15min, use a blank tube as a control, use a UV spectrophotometer , Measure the absorbance at a wavelength of 500nm to obtain a calibration curve of concentration C and absorbance A: C=72.714A-0.5268, r=0.9991.
②总黄酮含量的测定② Determination of total flavonoid content
精密吸取黄酮提取液1.0ml置于10ml容量瓶中,加水至2.4ml,加入质量分数为5%亚硝酸钠0.4ml摇匀,放置6min,加入质量分数为10%硝酸铝0.4ml,摇匀,放置6min,加入质量分数为4.3%氢氧化钠4.0ml,再加水至刻度,摇匀,放置15min,以空白试剂管为对照。用紫外分光光度计,在500nm波长处测定吸光度(全波长扫描,在500nm处显示吸收峰),代入回归方程,计算得总黄酮含量。Precisely draw 1.0ml of flavonoid extract and place it in a 10ml volumetric flask, add water to 2.4ml, add 0.4ml of sodium nitrite with a mass fraction of 5%, shake well, let stand for 6min, add 0.4ml of aluminum nitrate with a mass fraction of 10%, shake well, Stand for 6 minutes, add 4.0ml of sodium hydroxide with a mass fraction of 4.3%, add water to the mark, shake well, let stand for 15 minutes, and use a blank reagent tube as a control. Using a UV spectrophotometer, measure the absorbance at a wavelength of 500nm (full-wavelength scanning, showing an absorption peak at 500nm), and substitute it into the regression equation to calculate the total flavonoid content.
三、动物实验3. Animal experiments
1.接种瘤细胞1. Inoculation of tumor cells
雌性昆明小鼠40只,体重(25±2)g,实验第一天,每只小鼠均腋腔注射S180小鼠腹水(含瘤细胞株)0.2ml。40 female Kunming mice, weighing (25±2) g, were injected with 0.2 ml of S 180 mouse ascites (containing tumor cell line) in the axillary cavity on the first day of the experiment.
2.分组2. Grouping
将接种后的小鼠随机分为4组(生理盐水对照组、顺铂损伤模型对照组、低剂量马齿苋药物治疗组、高剂量马齿苋药物治疗组),每组10只。The inoculated mice were randomly divided into 4 groups (normal saline control group, cisplatin injury model control group, low dose purslane drug treatment group, high dose purslane drug treatment group), 10 in each group.
3.分组处理3. Packet processing
小鼠分组处理情况如下:The mice were divided into groups as follows:
1)生理盐水对照组:接种24小时后,每天用生理盐水灌胃0.5ml,一共7天;1) Normal saline control group: 24 hours after inoculation, 0.5ml of normal saline was administered into the stomach every day for a total of 7 days;
2)顺铂损伤模型对照组:接种24小时后,每天用生理盐水灌胃0.5ml,连续7天,于第4天一次性腹腔注射顺铂(12.0mg/kg);2) Cisplatin injury model control group: 24 hours after inoculation, 0.5ml of normal saline was administered into the stomach every day for 7 consecutive days, and cisplatin (12.0mg/kg) was injected intraperitoneally once on the fourth day;
3)马齿苋总黄酮低剂量给药组:每天用马齿苋提取物按照小鼠体重5mg/kg的比例灌胃一次(0.5ml),连续7天,于第4天一次性腹腔注射顺铂(12.0mg/kg);3) Low-dose administration group of total flavonoids of purslane: the extract of purslane was administered once a day (0.5ml) according to the ratio of mouse body weight 5mg/kg, for 7 consecutive days, and on the 4th day, a one-time intraperitoneal injection was given. Platinum (12.0mg/kg);
4)高剂量马齿苋提取物治疗组:每天用马齿苋提取物按照小鼠体重20mg/kg比例灌胃一次(0.5ml),连续7天,于第4天一次性腹腔注射顺铂(12.0mg/kg)。4) High-dose purslane extract treatment group: use purslane extract once a day (0.5ml) according to the ratio of mouse body weight 20mg/kg, for 7 consecutive days, and inject cisplatin ( 12.0 mg/kg).
4.取血、称瘤重4. Take blood and weigh the tumor
灌胃第七天,将小鼠眼球取血于试管中,然后处死小鼠并取出其腋下的瘤块,称重、记录。On the seventh day of gavage, blood was taken from the eyeballs of the mice in a test tube, and then the mice were sacrificed and the tumor mass in the armpit was taken out, weighed and recorded.
5.获取血清5. Get the Serum
小鼠眼球取血后,立即将装血液的试管放入冰箱中,30min后取出离心10min,吸取上层淡黄色透明液体,即血清。After taking blood from the mouse eyeball, immediately put the test tube containing the blood into the refrigerator, take it out after 30 minutes and centrifuge it for 10 minutes, and absorb the upper layer of light yellow transparent liquid, namely serum.
6.血尿素氮(BUN)含量测定6. Determination of blood urea nitrogen (BUN) content
按照表1向试管中加入试剂Add reagents to test tubes according to Table 1
表1 BUN含量测定方案Table 1 BUN content determination scheme
混匀所加试剂,置水中准确水浴15min,立即用自来水冷却。用波长520nm,1cm光径玻璃比色皿,空白管或蒸馏水调零,测定OD值。然后,根据OD值计算出血尿素氮的含量。Mix the added reagents, place in water for 15 minutes, and immediately cool with tap water. Use a glass cuvette with a wavelength of 520nm and an optical path of 1cm, a blank tube or distilled water to adjust to zero, and measure the OD value. Then, the blood urea nitrogen content was calculated according to the OD value.
7.血肌酐含量测定7. Determination of blood creatinine content
取血清0.2ml于试管中,加入钨酸蛋白沉淀试剂2ml,充分混匀,3000r/min,离心10min,取上清按表2进行测定Take 0.2ml of serum into a test tube, add 2ml of tungstic acid protein precipitation reagent, mix well, centrifuge at 3000r/min for 10min, take the supernatant and measure it according to Table 2
表2 血肌酐含量测定方案Table 2 Determination scheme of blood creatinine content
混匀所加试剂,37℃水浴10min,取出后流水冷却,1cm光径,510nm波长,空白管或蒸馏水调零,测定OD值。最后,根据OD值算出血肌酐的含量。Mix the added reagents, 37 ° C water bath for 10 minutes, take it out and cool it with running water, 1 cm optical path, 510 nm wavelength, zero the blank tube or distilled water, and measure the OD value. Finally, the content of blood creatinine was calculated according to the OD value.
四、实验结果4. Experimental results
1.瘤重1. Tumor weight
解剖小鼠,取出全部瘤块称取重量,单位为“克”。结果,马齿苋高、低剂量提取物组瘤重与顺铂损伤模型组相比无显著差异,提示高、低剂量马齿苋提取物对顺铂治疗肿瘤无明显的辅助作用(表3)。The mice were dissected, all the tumors were taken out and the weight was weighed, and the unit was "gram". As a result, there was no significant difference in tumor weight between the high and low doses of purslane extract group and the cisplatin injury model group, suggesting that high and low doses of purslane extract had no significant auxiliary effect on cisplatin treatment of tumors (Table 3) .
表3 各组小鼠瘤重比较(x±s)Table 3 Comparison of tumor weight of mice in each group (x±s)
与生理盐水组比较*P<0.05Compared with normal saline group * P<0.05
2.血清尿素氮(BUN)、肌酐(Cr)浓度测定2. Determination of serum urea nitrogen (BUN) and creatinine (Cr) concentrations
结果,顺铂损伤模型组血尿素氮与生理盐水组相比有显著差别,提示一次性给予大剂量的顺铂对肾有损伤作用。高、低剂量马齿苋提取物组血肌酐与顺铂损伤模型组相比无显著差异,但血尿素氮较顺铂损伤模型组相比显著降低,提示高、低剂量马齿苋提取物对顺铂引起的肾损伤有保护作用(表4)。As a result, the blood urea nitrogen of the cisplatin injury model group was significantly different from that of the normal saline group, suggesting that one-time administration of large doses of cisplatin can damage the kidneys. Compared with the cisplatin injury model group, the serum creatinine of the high and low doses of purslane extract group had no significant difference, but the blood urea nitrogen was significantly lower than that of the cisplatin injury model group, suggesting that the high and low doses of purslane extract had a significant effect on Cisplatin-induced renal injury was protective (Table 4).
表4 各组小鼠血尿素氮值比较(x±s,mmol/L)Table 4 Comparison of blood urea nitrogen values of mice in each group (x±s, mmol/L)
与生理盐水组比较,**P<0.01;与顺铂损伤模型组比较,#P<0.05。Compared with normal saline group, ** P<0.01; compared with cisplatin injury model group, # P<0.05.
五结论Five conclusions
上述实验结果表明,马齿苋提取物对顺铂治疗肿瘤无明显的辅助作用,但对顺铂所造成的肾损伤具有明显的保护作用。The above experimental results show that the extract of purslane has no obvious adjuvant effect on cisplatin treatment of tumors, but has obvious protective effect on kidney damage caused by cisplatin.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101976472A CN101401830B (en) | 2008-11-14 | 2008-11-14 | Preparation method for extracting flavone from purslane and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101976472A CN101401830B (en) | 2008-11-14 | 2008-11-14 | Preparation method for extracting flavone from purslane and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101401830A CN101401830A (en) | 2009-04-08 |
CN101401830B true CN101401830B (en) | 2011-04-20 |
Family
ID=40536079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101976472A Expired - Fee Related CN101401830B (en) | 2008-11-14 | 2008-11-14 | Preparation method for extracting flavone from purslane and uses thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101401830B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101708199A (en) * | 2009-11-13 | 2010-05-19 | 段洪东 | Purification method of purslane seed total flavonoid resin |
CN102526138B (en) * | 2012-01-19 | 2016-02-24 | 贾晓斌 | Composition of active components from fresh purslane for decreasing blood sugar and preparation method |
JP5763146B2 (en) * | 2013-10-10 | 2015-08-12 | 花王株式会社 | IGFBP-5 expression inhibitor |
JP5763145B2 (en) * | 2013-10-10 | 2015-08-12 | 花王株式会社 | IGFBP-5 expression inhibitor |
CN104059774B (en) * | 2014-06-30 | 2016-05-11 | 新疆大学 | A kind of method of preparing purslane polyunsaturated fatty acid from purslane slag |
CN105640842B (en) * | 2016-02-24 | 2017-05-31 | 广州市禾基生物科技有限公司 | A kind of preparation method of Purslane extract |
CN107998113B (en) * | 2018-01-08 | 2019-12-10 | 武汉大学 | Application of flavonoid compound CH625 in the preparation of anti-glioma drugs |
CN108785341A (en) * | 2018-08-27 | 2018-11-13 | 维康腾达生物科技有限公司 | A kind of preparation method of purslane extract |
CN109432144A (en) * | 2018-11-26 | 2019-03-08 | 张世华 | A kind of method that purslane extracts flavones |
-
2008
- 2008-11-14 CN CN2008101976472A patent/CN101401830B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101401830A (en) | 2009-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101401830B (en) | Preparation method for extracting flavone from purslane and uses thereof | |
CN101002841B (en) | Effective parts of rose and preparation method thereof | |
CN102145062B (en) | Active extracts of rosa roxburghii tratt fruit, and preparation method, detection method and application thereof | |
CN1931270B (en) | Sobering up and liver protecting Chinese medicine preparation and its preparation process | |
CN102274244B (en) | Cassia bark polyphenol extract and preparation method and application thereof | |
EP3275455B1 (en) | Pharmaceutical composition containing silybin and l-carnitine | |
CN103768152A (en) | Osmanthus phenylethanoid glycoside extract, and preparation method and application thereof | |
CN100566728C (en) | A kind of extraction method of high-purity tartary buckwheat flavonoids | |
TWI492755B (en) | Extract of toona sinensis from supercritical fluid extraction for treating diabetes and metabolic diseases, the preparation method and the use thereof | |
CN101401829A (en) | Wild Jinchai active extract and preparation method and application thereof | |
CN103494997B (en) | Traditional Chinese sophora flower medicine for treating hyperglycemia and diabetes | |
CN102091088A (en) | Applications of opuntia ficus-indica milpa alta polysaccharides in preventing and treating chronic neurodegenerative diseases | |
CN111919982A (en) | Natural plant beverage for relieving alcoholism and preparation method thereof | |
CN114452354B (en) | Traditional Chinese medicine composition for wounds, extract and application thereof | |
CN116076608A (en) | Banqing throat-moistening candy with antioxidant activity and preparation method thereof | |
CN116138455A (en) | Panax notoginseng polysaccharide extract and its application in the preparation of anti-fatigue products | |
CN100569234C (en) | Composition of total ginkgolides with neuroprotective effect | |
CN103664568B (en) | Dendrobium loddigesii Rolfe dimerization stilbene compound and its preparation method and application | |
CN102293796A (en) | Active part of lysimachia trientaloides Hemsl., and extraction method and application of active part | |
CN102204990B (en) | Medicine extract for reducing sugar content and preventing diabetic angiopathy and preparation method thereof | |
CN101732545B (en) | Preparation of compound extract of anemarrhena, astragalus and bitter gourd and use thereof | |
CN111888431A (en) | Composition for treating diabetes and preparation method thereof | |
CN111407836A (en) | A compound wine with blood pressure lowering, blood lipid reducing, and blood sugar lowering effects, and its preparation method | |
CN117959246B (en) | Extraction method of Corydalis mongolica, Corydalis mongolica anti-inflammatory ointment, and preparation method and application thereof | |
CN105168398A (en) | Pharmaceutical composition for treating nephropathy and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110420 Termination date: 20111114 |